Illinois-based Envoy Solutions, a diversified distribution company, recently agreed to purchase Philadelphia-based Penn Jersey Paper Co. (PJP) for an undisclosed amount.
The purchase is part of Envoy Solutions’ strategy to build a national platform. In addition, the purchase helps the company address the increased demand for essential products caused by the COVID-19 pandemic.
Founded in 1963, PJP is a distributor providing a vast portfolio of disposable packaging products and services to hospitals, schools, supermarkets, bars, and restaurants. It has a significant presence in the Mid-Atlantic.
“Our objective was to align ourselves with a partner who values the strength of the PJP brand and whose culture aligns with our Think Customer First strategy,” Thomas R. Furia Jr., PJP president, said. “Envoy Solutions provides us with the resources to broaden our position in the Mid-Atlantic and Northeast marketplaces. With the addition of PJP, the Envoys Solutions team is enhancing their product offering of foodservice disposables. By joining Envoy Solutions, we are well-positioned to expand our jan-san and commercial foodservice equipment and supplies business. We are excited about our future!”
PJP has 2,000 customers in Pennsylvania, New Jersey, Delaware, Maryland, New York, and Virginia.
The combined company will support more than 45,000 customers nationwide, operate 42 distribution centers, and employ more than 2,200.
Pennsylvania Senate President Pro Tempore Sen. Kim Ward (R-Westmoreland County) urged President Joe Biden to…
Vittoria Biotherapeutics, a clinical-stage cell therapy company, recently named Keith Westby as the company’s first…
Trumbauersville-based Bracalente Manufacturing Group, a manufacturing, supply chain, and logistics solutions provider, recently named Chris…
The U.S. House Ways & Means Committee recently held a hearing addressing trade and urged…
Pennsylvania will receive more than $21 million in federal money to address the health and…
Plymouth Meeting-based Harmony Biosciences Holdings, a company developing treatments for rare neurological diseases, recently signed…
This website uses cookies.